PDCD1 and neoplasm: Atezolizumab, an immune checkpoint inhibitor (ICI), targets programmed death 1 ligand 1 (PD-L1) to block its interaction with its receptors programmed cell death protein 1 (PD-1) and B7-1, which relieves the suppression of T cells and tumor immune escape (Herbst et al., 2014).